invivodata and Dendrite Announce Strategic Relationship

PITTSBURGH and BEDMINSTER, N.J. -- June 14, 2005 -- invivodata inc., an industry leader in electronic patient reported outcomes (ePRO) solutions for global clinical research, and Dendrite International Inc. (NASDAQ: DRTE), a leading provider of sales, marketing, clinical and compliance solutions for the pharmaceutical and life sciences industry, today announced a strategic relationship in which Dendrite will deliver key worldwide distribution and technical help desk services to support clinical trials utilizing invivodata's ePRO data collection systems, DiaryPRO and SitePRO.

This relationship will enable invivodata to leverage Dendrite's scalable worldwide distribution system and comprehensive IT and telephony infrastructure to seamlessly implement its electronic diary system in clinical trials sponsored by its pharmaceutical, biotech and medical device clients worldwide. Clinical trial sponsors will benefit from both companies' deep pharmaceutical knowledge and the stability, scalability and flexibility delivered by this collaboration.

"By working with Dendrite on a global basis, we expand our ability to deliver the high levels of professional service and satisfaction that our clients expect," said Doug Engfer, president and CEO of invivodata. "As a leading provider of distribution and help desk services, Dendrite is uniquely capable of supporting invivodata as we expand our business and meet the needs of our growing international client base."

invivodata combines behavioral and clinical science with handheld and Web technology to deliver real-time and site-based PRO data in clinical trials. As a result, sponsors capture PRO data of the highest integrity and benefit from increased study sensitivity and maximized regulatory confidence in the trial data.

Dendrite's help desk services, which are part of its First Source Trial Services' suite of solutions, will enable invivodata's customers to receive timely and accurate responses to all support requests on a 24x7 basis. Through Dendrite, invivodata's clients will gain access to benefits such as a single point of contact, highly trained support staff and a more personalized approach that Dendrite offers across all contact points, enabling a measurable increase in satisfaction for invivodata customers.

"We are pleased that through our strategic relationship, invivodata is able to leverage our distribution and help desk services to more efficiently deliver its high-quality PRO solutions on a global scale," said Paul Zaffaroni, president and chief operating officer at Dendrite. "Our world-class support services have helped companies of all sizes enhance their ability to respond to user needs. We look forward to supporting clinical trials utilizing invivodata's eDiary system with our global and scalable services."

About Dendrite
Founded in 1986, Dendrite International (NASDAQ: DRTE) provides award-winning sales, marketing, clinical and compliance solutions and services to global pharmaceutical and other life sciences companies. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

About invivodata inc.
invivodata (www.invivodata.com) combines behavioral science, information technology and clinical expertise to capture clinical trial data of the highest integrity directly from patients. invivodata's electronic patient reported outcomes (PRO) system delivers high-quality patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague self-report studies. The invivodata solution, which includes DiaryPRO for real-time PRO data collection and SitePRO for site-based PRO data collection, provides access to study data, giving researchers and sponsors visibility into study progress and improving trial efficiencies. invivodata's solution has been used in more than 100 trials involving over 35,000 patients. It has also collected nearly 50 million patient-initiated records, and is the only eDiary system that has delivered the primary efficacy data for FDA drug approval. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters are in London, England; and its technology development center is in Scotts Valley, Calif., USA.